Genetic Technologies' Expansion in North America

Genetic Technologies Limited (ASX: $GTG) has announced the commencement of testing operations in the United States for its geneType genetic risk assessment product series. The company has partnered with Gene by Gene, a premier specialty genetic laboratory based in Houston, Texas, to perform its multi-patented, clinically validated tests. This expansion significantly increases geneType's operational capacity in North America and is expected to shorten the turn-around time for samples sent in from the region.

Executive Commentary on Expansion

As personalized medicine and health-consciousness continue to trend upwards, we are confident that the uniquely integrated, highly accurate geneType test will continue to meet the rising demand for personalized, actionable health information. Our collaboration with Gene by Gene and Stayhealthy solidifies the infrastructure needed to deliver that information so that individuals and healthcare providers in North America can take control of their health.

Summary of Genetic Technologies' Expansion

Genetic Technologies Limited (ASX: $GTG) has expanded its operational capacity in North America by launching testing operations for its geneType genetic risk assessment product series at the world-leading genetic laboratory, Gene by Gene. This strategic move is expected to facilitate exponential growth across North America, supported by the recent distribution agreement with Stayhealthy. The company's geneType tests, which cover a wide range of diseases and conditions, are poised to reach a broader consumer base through Stayhealthy's partnership, thereby empowering individuals to take control of their health. Genetic Technologies continues to lead in risk prediction in oncology, cardiovascular, and metabolic diseases, and is focused on developing further risk assessment products to improve health outcomes globally.